university of kwazulu-natal faculty of science and agriculture school ...

Table 28: Growth inhibition values for compounds I-IV against TK-10, UACC-62
and MCF-7 cell lines
Compound
I
II
III
IV
Doseresponse
parameters
Line 1
(TK-10)
renal
Line 2
(UACC-62)
melanoma
Line 3
(MCF-7)
breast
GI50 21.02 13.42 20.57
TGI 49.10 44.71 51.20
LC50 77.18 76.00 81.84
LC100 N/A N/A N/A
GI50 24.06 12.05 23.63
TGI 55.84 42.18 52.72
LC50 87.63 72.32 81.82
LC100 N/A N/A N/A
GI50 26.50 13.53 39.08
TGI 53.99 44.64 81.22
LC50 81.48 75.74 N/A
LC100 N/A N/A N/A
GI50 N/A 48.67 92.57
TGI N/A N/A N/A
LC50 N/A N/A N/A
LC100 N/A N/A N/A
Etoposide TGI 27.00 36.20 >100
NB. N/A denotes inactivity
The GI50 values for compounds I and II are compared to that of their isomers (Gaspar-
Marques et al., 2002) in Table 29. In our results, the GI50 values of both I and II are
similar. However, this is not the case with the GI50 values for the isomers, compounds 33
and 36 reported in the literature. Compound 36 displayed significantly better activity
than any of the other three compounds against the three cell lines used. Our two
compounds I and II however showed better activity than the dihydroxy isomer (33).
Table 29: GI50 values (µM) of compounds I and II and their 7α-isomers
Compound
MCF-7
Cell line
TK-10 UACC-62
I 34.41 53.90 52.74
36 6.4 7.4 4.5
II 34.63 69.14 67.90
33 48.3 107.6 77.9
Doxorubicin 0.055 0.570 0.094
152